Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Identifieur interne : 002120 ( PubMed/Checkpoint ); précédent : 002119; suivant : 002121Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Auteurs : Peter Reichardt [Allemagne] ; George D. Demetri [États-Unis] ; Hans Gelderblom [Pays-Bas] ; Piotr Rutkowski [Pologne] ; Seock-Ah Im [Corée du Sud] ; Sudeep Gupta [Inde] ; Yoon-Koo Kang [Corée du Sud] ; Patrick Schöffski [Belgique] ; Jochen Schuette [Allemagne] ; Denis Soulières [Canada] ; Jean-Yves Blay [France] ; David Goldstein [Australie] ; Kolette Fly [États-Unis] ; Xin Huang [États-Unis] ; Massimo Corsaro [Italie] ; Maria Jose Lechuga [Italie] ; Jean-Francois Martini [États-Unis] ; Michael C. Heinrich [États-Unis]Source :
- BMC cancer [ 1471-2407 ] ; 2016.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, Génotype, Humains, Indoles (administration et posologie), Indoles (effets indésirables), Inhibiteurs de protéines kinases (administration et posologie), Mutation, Mâle, Pronostic, Protéines proto-oncogènes c-kit (génétique), Pyrroles (administration et posologie), Pyrroles (effets indésirables), Récepteur au PDGF alpha (génétique), Résistance aux médicaments antinéoplasiques (génétique), Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Tumeurs stromales gastro-intestinales (anatomopathologie), Tumeurs stromales gastro-intestinales (génétique), Tumeurs stromales gastro-intestinales (traitement médicamenteux).
- MESH :
- administration et posologie : Indoles, Inhibiteurs de protéines kinases, Pyrroles.
- anatomopathologie : Tumeurs stromales gastro-intestinales.
- effets indésirables : Indoles, Pyrroles.
- génétique : Protéines proto-oncogènes c-kit, Récepteur au PDGF alpha, Résistance aux médicaments antinéoplasiques, Tumeurs stromales gastro-intestinales.
- traitement médicamenteux : Tumeurs stromales gastro-intestinales.
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, Génotype, Humains, Mutation, Mâle, Pronostic, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Disease-Free Survival, Drug Resistance, Neoplasm (genetics), Female, Gastrointestinal Stromal Tumors (drug therapy), Gastrointestinal Stromal Tumors (genetics), Gastrointestinal Stromal Tumors (pathology), Genotype, Humans, Indoles (administration & dosage), Indoles (adverse effects), Male, Middle Aged, Mutation, Prognosis, Protein Kinase Inhibitors (administration & dosage), Proto-Oncogene Proteins c-kit (genetics), Pyrroles (administration & dosage), Pyrroles (adverse effects), Receptor, Platelet-Derived Growth Factor alpha (genetics).
- MESH :
- chemical , administration & dosage : Indoles, Protein Kinase Inhibitors, Pyrroles.
- chemical , adverse effects : Indoles, Pyrroles.
- drug therapy : Gastrointestinal Stromal Tumors.
- genetics : Drug Resistance, Neoplasm, Gastrointestinal Stromal Tumors, Proto-Oncogene Proteins c-kit, Receptor, Platelet-Derived Growth Factor alpha.
- pathology : Gastrointestinal Stromal Tumors.
- Adolescent, Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Genotype, Humans, Male, Middle Aged, Mutation, Prognosis.
Abstract
Several small studies indicated that the genotype of KIT or platelet-derived growth factor receptor-α (PDGFRA) contributes in part to the level of clinical effectiveness of sunitinib in gastrointestinal stromal tumor (GIST) patients. This study aimed to correlate KIT and PDGFRA mutational status with clinical outcome metrics (progression-free survival [PFS], overall survival [OS], objective response rate [ORR]) in a larger international patient population.
DOI: 10.1186/s12885-016-2051-5
PubMed: 26772734
Affiliations:
- Allemagne, Australie, Belgique, Canada, Corée du Sud, France, Inde, Italie, Pays-Bas, Pologne, États-Unis
- Auvergne-Rhône-Alpes, Berlin, Californie, Connecticut, District de Düsseldorf, Hollande-Méridionale, Lombardie, Massachusetts, Nouvelle-Galles du Sud, Oregon, Rhénanie-du-Nord-Westphalie, Rhône-Alpes, Région capitale de Séoul
- Berlin, Düsseldorf, Leyde, Lyon, Milan, Sydney, Séoul
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26772734Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.</title><author><name sortKey="Reichardt, Peter" sort="Reichardt, Peter" uniqKey="Reichardt P" first="Peter" last="Reichardt">Peter Reichardt</name><affiliation wicri:level="3"><nlm:affiliation>Department of Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany. peter.reichardt@helios-kliniken.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Demetri, George D" sort="Demetri, George D" uniqKey="Demetri G" first="George D" last="Demetri">George D. Demetri</name><affiliation wicri:level="2"><nlm:affiliation>Ludwig Center at Harvard and Dana-Farber Cancer Institute, Boston, MA, USA. george_demetri@dfci.harvard.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Ludwig Center at Harvard and Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Gelderblom, Hans" sort="Gelderblom, Hans" uniqKey="Gelderblom H" first="Hans" last="Gelderblom">Hans Gelderblom</name><affiliation wicri:level="3"><nlm:affiliation>Leiden University Medical Center, Leiden, The Netherlands. a.j.gelderblom@lumc.nl.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Leiden University Medical Center, Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Rutkowski, Piotr" sort="Rutkowski, Piotr" uniqKey="Rutkowski P" first="Piotr" last="Rutkowski">Piotr Rutkowski</name><affiliation wicri:level="1"><nlm:affiliation>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. rutkowskip@coi.waw.pl.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Im, Seock Ah" sort="Im, Seock Ah" uniqKey="Im S" first="Seock-Ah" last="Im">Seock-Ah Im</name><affiliation wicri:level="3"><nlm:affiliation>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. moisa@snu.ac.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Gupta, Sudeep" sort="Gupta, Sudeep" uniqKey="Gupta S" first="Sudeep" last="Gupta">Sudeep Gupta</name><affiliation wicri:level="1"><nlm:affiliation>Tata Memorial Centre, Mumbai, India. sudeepgupta04@yahoo.com.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Tata Memorial Centre, Mumbai</wicri:regionArea><wicri:noRegion>Mumbai</wicri:noRegion></affiliation></author><author><name sortKey="Kang, Yoon Koo" sort="Kang, Yoon Koo" uniqKey="Kang Y" first="Yoon-Koo" last="Kang">Yoon-Koo Kang</name><affiliation wicri:level="3"><nlm:affiliation>Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. ykkang@amc.seoul.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Asan Medical Center, University of Ulsan College of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Schoffski, Patrick" sort="Schoffski, Patrick" uniqKey="Schoffski P" first="Patrick" last="Schöffski">Patrick Schöffski</name><affiliation wicri:level="1"><nlm:affiliation>University Hospitals Leuven, Leuven Cancer Institute, and Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium. patrick.schoffski@uz.kuleuven.ac.be.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>University Hospitals Leuven, Leuven Cancer Institute, and Laboratory of Experimental Oncology, KU Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Schuette, Jochen" sort="Schuette, Jochen" uniqKey="Schuette J" first="Jochen" last="Schuette">Jochen Schuette</name><affiliation wicri:level="3"><nlm:affiliation>Hämatoonkologische Schwerpunktpraxis, Düsseldorf, Germany. jochen.schuette@uni-duisburg-essen.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Hämatoonkologische Schwerpunktpraxis, Düsseldorf</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Düsseldorf</region><settlement type="city">Düsseldorf</settlement></placeName></affiliation></author><author><name sortKey="Soulieres, Denis" sort="Soulieres, Denis" uniqKey="Soulieres D" first="Denis" last="Soulières">Denis Soulières</name><affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada. denis.soulieres@umontreal.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre Hospitalier de l'Université de Montreal, Montreal, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><affiliation wicri:level="3"><nlm:affiliation>Centre Léon Bérard, Université Claude Bernard, Lyon, France. jean-yves.blay@lyon.unicancer.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Léon Bérard, Université Claude Bernard, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Goldstein, David" sort="Goldstein, David" uniqKey="Goldstein D" first="David" last="Goldstein">David Goldstein</name><affiliation wicri:level="3"><nlm:affiliation>Prince of Wales Hospital, Sydney, Australia. d.goldstein@unsw.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Prince of Wales Hospital, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Fly, Kolette" sort="Fly, Kolette" uniqKey="Fly K" first="Kolette" last="Fly">Kolette Fly</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, Groton, CT, USA. kolette.d.fly@pfizer.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, Groton, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Huang, Xin" sort="Huang, Xin" uniqKey="Huang X" first="Xin" last="Huang">Xin Huang</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, La Jolla, CA, USA. xin.huang@pfizer.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, La Jolla, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Corsaro, Massimo" sort="Corsaro, Massimo" uniqKey="Corsaro M" first="Massimo" last="Corsaro">Massimo Corsaro</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer Oncology, Milan, Italy. massimo.corsaro@pfizer.com.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pfizer Oncology, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Lechuga, Maria Jose" sort="Lechuga, Maria Jose" uniqKey="Lechuga M" first="Maria Jose" last="Lechuga">Maria Jose Lechuga</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer Oncology, Milan, Italy. mariajose.lechuga@pfizer.com.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pfizer Oncology, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Martini, Jean Francois" sort="Martini, Jean Francois" uniqKey="Martini J" first="Jean-Francois" last="Martini">Jean-Francois Martini</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, La Jolla, CA, USA. jean-francois.martini@pfizer.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, La Jolla, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Heinrich, Michael C" sort="Heinrich, Michael C" uniqKey="Heinrich M" first="Michael C" last="Heinrich">Michael C. Heinrich</name><affiliation wicri:level="2"><nlm:affiliation>VA Portland Health Care System and Oregon Health & Science University, Portland, OR, USA. heinrich@ohsu.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>VA Portland Health Care System and Oregon Health & Science University, Portland, OR</wicri:regionArea><placeName><region type="state">Oregon</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26772734</idno><idno type="pmid">26772734</idno><idno type="doi">10.1186/s12885-016-2051-5</idno><idno type="wicri:Area/PubMed/Corpus">002483</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002483</idno><idno type="wicri:Area/PubMed/Curation">002434</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002434</idno><idno type="wicri:Area/PubMed/Checkpoint">002434</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002434</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.</title><author><name sortKey="Reichardt, Peter" sort="Reichardt, Peter" uniqKey="Reichardt P" first="Peter" last="Reichardt">Peter Reichardt</name><affiliation wicri:level="3"><nlm:affiliation>Department of Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany. peter.reichardt@helios-kliniken.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Demetri, George D" sort="Demetri, George D" uniqKey="Demetri G" first="George D" last="Demetri">George D. Demetri</name><affiliation wicri:level="2"><nlm:affiliation>Ludwig Center at Harvard and Dana-Farber Cancer Institute, Boston, MA, USA. george_demetri@dfci.harvard.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Ludwig Center at Harvard and Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Gelderblom, Hans" sort="Gelderblom, Hans" uniqKey="Gelderblom H" first="Hans" last="Gelderblom">Hans Gelderblom</name><affiliation wicri:level="3"><nlm:affiliation>Leiden University Medical Center, Leiden, The Netherlands. a.j.gelderblom@lumc.nl.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Leiden University Medical Center, Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Rutkowski, Piotr" sort="Rutkowski, Piotr" uniqKey="Rutkowski P" first="Piotr" last="Rutkowski">Piotr Rutkowski</name><affiliation wicri:level="1"><nlm:affiliation>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. rutkowskip@coi.waw.pl.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Im, Seock Ah" sort="Im, Seock Ah" uniqKey="Im S" first="Seock-Ah" last="Im">Seock-Ah Im</name><affiliation wicri:level="3"><nlm:affiliation>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. moisa@snu.ac.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Gupta, Sudeep" sort="Gupta, Sudeep" uniqKey="Gupta S" first="Sudeep" last="Gupta">Sudeep Gupta</name><affiliation wicri:level="1"><nlm:affiliation>Tata Memorial Centre, Mumbai, India. sudeepgupta04@yahoo.com.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Tata Memorial Centre, Mumbai</wicri:regionArea><wicri:noRegion>Mumbai</wicri:noRegion></affiliation></author><author><name sortKey="Kang, Yoon Koo" sort="Kang, Yoon Koo" uniqKey="Kang Y" first="Yoon-Koo" last="Kang">Yoon-Koo Kang</name><affiliation wicri:level="3"><nlm:affiliation>Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. ykkang@amc.seoul.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Asan Medical Center, University of Ulsan College of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Schoffski, Patrick" sort="Schoffski, Patrick" uniqKey="Schoffski P" first="Patrick" last="Schöffski">Patrick Schöffski</name><affiliation wicri:level="1"><nlm:affiliation>University Hospitals Leuven, Leuven Cancer Institute, and Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium. patrick.schoffski@uz.kuleuven.ac.be.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>University Hospitals Leuven, Leuven Cancer Institute, and Laboratory of Experimental Oncology, KU Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Schuette, Jochen" sort="Schuette, Jochen" uniqKey="Schuette J" first="Jochen" last="Schuette">Jochen Schuette</name><affiliation wicri:level="3"><nlm:affiliation>Hämatoonkologische Schwerpunktpraxis, Düsseldorf, Germany. jochen.schuette@uni-duisburg-essen.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Hämatoonkologische Schwerpunktpraxis, Düsseldorf</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Düsseldorf</region><settlement type="city">Düsseldorf</settlement></placeName></affiliation></author><author><name sortKey="Soulieres, Denis" sort="Soulieres, Denis" uniqKey="Soulieres D" first="Denis" last="Soulières">Denis Soulières</name><affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada. denis.soulieres@umontreal.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre Hospitalier de l'Université de Montreal, Montreal, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><affiliation wicri:level="3"><nlm:affiliation>Centre Léon Bérard, Université Claude Bernard, Lyon, France. jean-yves.blay@lyon.unicancer.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Léon Bérard, Université Claude Bernard, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Goldstein, David" sort="Goldstein, David" uniqKey="Goldstein D" first="David" last="Goldstein">David Goldstein</name><affiliation wicri:level="3"><nlm:affiliation>Prince of Wales Hospital, Sydney, Australia. d.goldstein@unsw.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Prince of Wales Hospital, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Fly, Kolette" sort="Fly, Kolette" uniqKey="Fly K" first="Kolette" last="Fly">Kolette Fly</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, Groton, CT, USA. kolette.d.fly@pfizer.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, Groton, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Huang, Xin" sort="Huang, Xin" uniqKey="Huang X" first="Xin" last="Huang">Xin Huang</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, La Jolla, CA, USA. xin.huang@pfizer.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, La Jolla, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Corsaro, Massimo" sort="Corsaro, Massimo" uniqKey="Corsaro M" first="Massimo" last="Corsaro">Massimo Corsaro</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer Oncology, Milan, Italy. massimo.corsaro@pfizer.com.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pfizer Oncology, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Lechuga, Maria Jose" sort="Lechuga, Maria Jose" uniqKey="Lechuga M" first="Maria Jose" last="Lechuga">Maria Jose Lechuga</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer Oncology, Milan, Italy. mariajose.lechuga@pfizer.com.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pfizer Oncology, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Martini, Jean Francois" sort="Martini, Jean Francois" uniqKey="Martini J" first="Jean-Francois" last="Martini">Jean-Francois Martini</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, La Jolla, CA, USA. jean-francois.martini@pfizer.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, La Jolla, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Heinrich, Michael C" sort="Heinrich, Michael C" uniqKey="Heinrich M" first="Michael C" last="Heinrich">Michael C. Heinrich</name><affiliation wicri:level="2"><nlm:affiliation>VA Portland Health Care System and Oregon Health & Science University, Portland, OR, USA. heinrich@ohsu.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>VA Portland Health Care System and Oregon Health & Science University, Portland, OR</wicri:regionArea><placeName><region type="state">Oregon</region></placeName></affiliation></author></analytic><series><title level="j">BMC cancer</title><idno type="eISSN">1471-2407</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disease-Free Survival</term><term>Drug Resistance, Neoplasm (genetics)</term><term>Female</term><term>Gastrointestinal Stromal Tumors (drug therapy)</term><term>Gastrointestinal Stromal Tumors (genetics)</term><term>Gastrointestinal Stromal Tumors (pathology)</term><term>Genotype</term><term>Humans</term><term>Indoles (administration & dosage)</term><term>Indoles (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>Mutation</term><term>Prognosis</term><term>Protein Kinase Inhibitors (administration & dosage)</term><term>Proto-Oncogene Proteins c-kit (genetics)</term><term>Pyrroles (administration & dosage)</term><term>Pyrroles (adverse effects)</term><term>Receptor, Platelet-Derived Growth Factor alpha (genetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Génotype</term><term>Humains</term><term>Indoles (administration et posologie)</term><term>Indoles (effets indésirables)</term><term>Inhibiteurs de protéines kinases (administration et posologie)</term><term>Mutation</term><term>Mâle</term><term>Pronostic</term><term>Protéines proto-oncogènes c-kit (génétique)</term><term>Pyrroles (administration et posologie)</term><term>Pyrroles (effets indésirables)</term><term>Récepteur au PDGF alpha (génétique)</term><term>Résistance aux médicaments antinéoplasiques (génétique)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Tumeurs stromales gastro-intestinales (anatomopathologie)</term><term>Tumeurs stromales gastro-intestinales (génétique)</term><term>Tumeurs stromales gastro-intestinales (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Indoles</term><term>Protein Kinase Inhibitors</term><term>Pyrroles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Indoles</term><term>Pyrroles</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Indoles</term><term>Inhibiteurs de protéines kinases</term><term>Pyrroles</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs stromales gastro-intestinales</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Gastrointestinal Stromal Tumors</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Indoles</term><term>Pyrroles</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Drug Resistance, Neoplasm</term><term>Gastrointestinal Stromal Tumors</term><term>Proto-Oncogene Proteins c-kit</term><term>Receptor, Platelet-Derived Growth Factor alpha</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Protéines proto-oncogènes c-kit</term><term>Récepteur au PDGF alpha</term><term>Résistance aux médicaments antinéoplasiques</term><term>Tumeurs stromales gastro-intestinales</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Gastrointestinal Stromal Tumors</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs stromales gastro-intestinales</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disease-Free Survival</term><term>Female</term><term>Genotype</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Mutation</term><term>Prognosis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Génotype</term><term>Humains</term><term>Mutation</term><term>Mâle</term><term>Pronostic</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Several small studies indicated that the genotype of KIT or platelet-derived growth factor receptor-α (PDGFRA) contributes in part to the level of clinical effectiveness of sunitinib in gastrointestinal stromal tumor (GIST) patients. This study aimed to correlate KIT and PDGFRA mutational status with clinical outcome metrics (progression-free survival [PFS], overall survival [OS], objective response rate [ORR]) in a larger international patient population.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26772734</PMID><DateCreated><Year>2016</Year><Month>01</Month><Day>16</Day></DateCreated><DateCompleted><Year>2016</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2407</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><PubDate><Year>2016</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>BMC cancer</Title><ISOAbbreviation>BMC Cancer</ISOAbbreviation></Journal><ArticleTitle>Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.</ArticleTitle><Pagination><MedlinePgn>22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-016-2051-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Several small studies indicated that the genotype of KIT or platelet-derived growth factor receptor-α (PDGFRA) contributes in part to the level of clinical effectiveness of sunitinib in gastrointestinal stromal tumor (GIST) patients. This study aimed to correlate KIT and PDGFRA mutational status with clinical outcome metrics (progression-free survival [PFS], overall survival [OS], objective response rate [ORR]) in a larger international patient population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a non-interventional, retrospective analysis in patients with imatinib-resistant or intolerant GIST who were treated in a worldwide, open-label treatment-use study (Study 1036; NCT00094029) in which sunitinib was administered at a starting dose of 50 mg/day on a 4-week-on, 2-week-off schedule. Molecular status was obtained in local laboratories with tumor samples obtained either pre-imatinib, post-imatinib/pre-sunitinib, or post-sunitinib treatment, and all available data were used in the analyses regardless of collection time. The primary analysis compared PFS in patients with primary KIT exon 11 versus exon 9 mutations (using a 2-sided log-rank test) and secondary analyses compared OS (using the same test) and ORR (using a 2-sided Pearson χ(2) test) in the same molecular subgroups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 1124 sunitinib-treated patients in the treatment-use study, 230 (20%) were included in this analysis, and baseline characteristics were similar between the two study populations. Median PFS was 7.1 months. A significantly better PFS was observed in patients with a primary mutation in KIT exon 9 (n = 42) compared to those with a primary mutation in exon 11 (n = 143; hazard ratio = 0.59; 95 % confidence interval, 0.39-0.89; P = 0.011), with median PFS times of 12.3 and 7.0 months, respectively. Similarly, longer OS and higher ORR were observed in patients with a primary KIT mutation in exon 9 versus exon 11. The data available were limited to investigate the effects of additional KIT or PDGFRA mutations on the efficacy of sunitinib treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This large retrospective analysis confirms the prognostic significance of KIT mutation status in patients with GIST. This analysis also confirms the effectiveness of sunitinib as a post-imatinib therapy, regardless of mutational status.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">NCT01459757.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reichardt</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany. peter.reichardt@helios-kliniken.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demetri</LastName><ForeName>George D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Ludwig Center at Harvard and Dana-Farber Cancer Institute, Boston, MA, USA. george_demetri@dfci.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelderblom</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Leiden University Medical Center, Leiden, The Netherlands. a.j.gelderblom@lumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutkowski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. rutkowskip@coi.waw.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Im</LastName><ForeName>Seock-Ah</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. moisa@snu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Sudeep</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tata Memorial Centre, Mumbai, India. sudeepgupta04@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Yoon-Koo</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. ykkang@amc.seoul.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schöffski</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University Hospitals Leuven, Leuven Cancer Institute, and Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium. patrick.schoffski@uz.kuleuven.ac.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuette</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hämatoonkologische Schwerpunktpraxis, Düsseldorf, Germany. jochen.schuette@uni-duisburg-essen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soulières</LastName><ForeName>Denis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada. denis.soulieres@umontreal.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blay</LastName><ForeName>Jean-Yves</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Centre Léon Bérard, Université Claude Bernard, Lyon, France. jean-yves.blay@lyon.unicancer.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Prince of Wales Hospital, Sydney, Australia. d.goldstein@unsw.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fly</LastName><ForeName>Kolette</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Pfizer Oncology, Groton, CT, USA. kolette.d.fly@pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Pfizer Oncology, La Jolla, CA, USA. xin.huang@pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corsaro</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pfizer Oncology, Milan, Italy. massimo.corsaro@pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lechuga</LastName><ForeName>Maria Jose</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Pfizer Oncology, Milan, Italy. mariajose.lechuga@pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martini</LastName><ForeName>Jean-Francois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Pfizer Oncology, La Jolla, CA, USA. jean-francois.martini@pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heinrich</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>VA Portland Health Care System and Oregon Health & Science University, Portland, OR, USA. heinrich@ohsu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01459757</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P50 CA127003</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1P50CA127003-05</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cancer</MedlineTA><NlmUniqueID>100967800</NlmUniqueID><ISSNLinking>1471-2407</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D019009">Proto-Oncogene Proteins c-kit</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020796">Receptor, Platelet-Derived Growth Factor alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>V99T50803M</RegistryNumber><NameOfSubstance UI="C473478">sunitinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Pathol. 2008 Sep;216(1):64-74</RefSource><PMID Version="1">18623623</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2005 Jun 1;11(11):4182-90</RefSource><PMID Version="1">15930355</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Clin Oncol. 2009 Apr;14(2):143-9</RefSource><PMID Version="1">19390946</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2006 Oct 10;24(29):4764-74</RefSource><PMID Version="1">16954519</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Cancer. 2012;12:107</RefSource><PMID Version="1">22439647</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Nov 20;26(33):5352-9</RefSource><PMID Version="1">18955458</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2007 Jul 27;130(2):323-34</RefSource><PMID Version="1">17662946</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Feb 1;26(4):620-5</RefSource><PMID Version="1">18235121</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Histopathology. 2008 Sep;53(3):245-66</RefSource><PMID Version="1">18312355</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Invest New Drugs. 2012 Apr;30(2):819-27</RefSource><PMID Version="1">21104107</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2000 Feb 2;92(3):205-16</RefSource><PMID Version="1">10655437</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2004 Sep 1;64(17):5913-9</RefSource><PMID Version="1">15342366</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 2006 Oct;91(10):4070-6</RefSource><PMID Version="1">16849418</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Aug 20;23(24):5795-804</RefSource><PMID Version="1">16110036</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2002 Aug 15;347(7):472-80</RefSource><PMID Version="1">12181401</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2003 Jan 31;299(5607):708-10</RefSource><PMID Version="1">12522257</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Med Oncol. 2013 Jun;30(2):522</RefSource><PMID Version="1">23456621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Nov 20;26(33):5360-7</RefSource><PMID Version="1">18955451</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ther Adv Med Oncol. 2014 May;6(3):115-27</RefSource><PMID Version="1">24790651</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Pathol. 2002 May;160(5):1567-72</RefSource><PMID Version="1">12000708</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2003 Dec 1;21(23):4342-9</RefSource><PMID Version="1">14645423</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Gastrointestin Liver Dis. 2013 Dec;22(4):413-8</RefSource><PMID Version="1">24369323</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2015 May 1;121(9):1405-13</RefSource><PMID Version="1">25641662</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cancer Ther. 2003 May;2(5):471-8</RefSource><PMID Version="1">12748309</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2009 Jul;45(11):1959-68</RefSource><PMID Version="1">19282169</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2004 Sep;4(9):718-27</RefSource><PMID Version="1">15343278</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7</RefSource><PMID Version="1">19164557</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2004 May 15;10(10):3282-90</RefSource><PMID Version="1">15161681</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2003 May 1;101(9):3597-605</RefSource><PMID Version="1">12531805</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2006 Oct 14;368(9544):1329-38</RefSource><PMID Version="1">17046465</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2012 Jun 1;18(11):3170-9</RefSource><PMID Version="1">22661587</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2001 Nov 15;61(22):8118-21</RefSource><PMID Version="1">11719439</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Surg Pathol. 2013 Nov;37(11):1648-59</RefSource><PMID Version="1">24061512</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>World J Gastroenterol. 2012 Feb 21;18(7):698-703</RefSource><PMID Version="1">22363143</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2003 Jan;9(1):327-37</RefSource><PMID Version="1">12538485</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Pathol. 2008;3:557-86</RefSource><PMID Version="1">18039140</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2009 Sep 15;15(18):5902-9</RefSource><PMID Version="1">19737946</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046152" MajorTopicYN="N">Gastrointestinal Stromal Tumors</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019009" MajorTopicYN="N">Proto-Oncogene Proteins c-kit</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011758" MajorTopicYN="N">Pyrroles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020796" MajorTopicYN="N">Receptor, Platelet-Derived Growth Factor alpha</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4714485</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>07</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>01</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26772734</ArticleId><ArticleId IdType="doi">10.1186/s12885-016-2051-5</ArticleId><ArticleId IdType="pii">10.1186/s12885-016-2051-5</ArticleId><ArticleId IdType="pmc">PMC4714485</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>Canada</li><li>Corée du Sud</li><li>France</li><li>Inde</li><li>Italie</li><li>Pays-Bas</li><li>Pologne</li><li>États-Unis</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Berlin</li><li>Californie</li><li>Connecticut</li><li>District de Düsseldorf</li><li>Hollande-Méridionale</li><li>Lombardie</li><li>Massachusetts</li><li>Nouvelle-Galles du Sud</li><li>Oregon</li><li>Rhénanie-du-Nord-Westphalie</li><li>Rhône-Alpes</li><li>Région capitale de Séoul</li></region><settlement><li>Berlin</li><li>Düsseldorf</li><li>Leyde</li><li>Lyon</li><li>Milan</li><li>Sydney</li><li>Séoul</li></settlement></list><tree><country name="Allemagne"><region name="Berlin"><name sortKey="Reichardt, Peter" sort="Reichardt, Peter" uniqKey="Reichardt P" first="Peter" last="Reichardt">Peter Reichardt</name></region><name sortKey="Schuette, Jochen" sort="Schuette, Jochen" uniqKey="Schuette J" first="Jochen" last="Schuette">Jochen Schuette</name></country><country name="États-Unis"><region name="Massachusetts"><name sortKey="Demetri, George D" sort="Demetri, George D" uniqKey="Demetri G" first="George D" last="Demetri">George D. Demetri</name></region><name sortKey="Fly, Kolette" sort="Fly, Kolette" uniqKey="Fly K" first="Kolette" last="Fly">Kolette Fly</name><name sortKey="Heinrich, Michael C" sort="Heinrich, Michael C" uniqKey="Heinrich M" first="Michael C" last="Heinrich">Michael C. Heinrich</name><name sortKey="Huang, Xin" sort="Huang, Xin" uniqKey="Huang X" first="Xin" last="Huang">Xin Huang</name><name sortKey="Martini, Jean Francois" sort="Martini, Jean Francois" uniqKey="Martini J" first="Jean-Francois" last="Martini">Jean-Francois Martini</name></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Gelderblom, Hans" sort="Gelderblom, Hans" uniqKey="Gelderblom H" first="Hans" last="Gelderblom">Hans Gelderblom</name></region></country><country name="Pologne"><noRegion><name sortKey="Rutkowski, Piotr" sort="Rutkowski, Piotr" uniqKey="Rutkowski P" first="Piotr" last="Rutkowski">Piotr Rutkowski</name></noRegion></country><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Im, Seock Ah" sort="Im, Seock Ah" uniqKey="Im S" first="Seock-Ah" last="Im">Seock-Ah Im</name></region><name sortKey="Kang, Yoon Koo" sort="Kang, Yoon Koo" uniqKey="Kang Y" first="Yoon-Koo" last="Kang">Yoon-Koo Kang</name></country><country name="Inde"><noRegion><name sortKey="Gupta, Sudeep" sort="Gupta, Sudeep" uniqKey="Gupta S" first="Sudeep" last="Gupta">Sudeep Gupta</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="Schoffski, Patrick" sort="Schoffski, Patrick" uniqKey="Schoffski P" first="Patrick" last="Schöffski">Patrick Schöffski</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Soulieres, Denis" sort="Soulieres, Denis" uniqKey="Soulieres D" first="Denis" last="Soulières">Denis Soulières</name></noRegion></country><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name></region></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Goldstein, David" sort="Goldstein, David" uniqKey="Goldstein D" first="David" last="Goldstein">David Goldstein</name></region></country><country name="Italie"><region name="Lombardie"><name sortKey="Corsaro, Massimo" sort="Corsaro, Massimo" uniqKey="Corsaro M" first="Massimo" last="Corsaro">Massimo Corsaro</name></region><name sortKey="Lechuga, Maria Jose" sort="Lechuga, Maria Jose" uniqKey="Lechuga M" first="Maria Jose" last="Lechuga">Maria Jose Lechuga</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002120 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002120 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26772734
|texte= Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26772734" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |